| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $33.4M | -31.4% |
| SG&A Expense | $14.0M | -30.8% |
| Operating Income | -$47.5M | +31.2% |
| Net Income | -$46.8M | +34.8% |
| EPS (Basic) | -$45.05 | -10.0% |
| EPS (Diluted) | -$45.05 | -10.0% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $194.6M | +42.4% |
| Current Assets | $198.5M | +41.7% |
| Total Assets | $200.2M | +42.6% |
| Current Liabilities | $22.6M | +52.2% |
| Total Liabilities | $23.6M | +51.4% |
| Stockholders' Equity | $176.6M | +41.5% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$42.3M | +29.2% |
| Capital Expenditures | $151K | +112.7% |
| Investing Cash Flow | -$151K | -143.9% |
| Financing Cash Flow | $149.0M | -22.2% |
| Free Cash Flow | -$42.4M | +29.1% |